FAIRFIELD, Conn., March 11, 2011 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) today announced that researchers at the University of Wisconsin’s Carbone Cancer Center have begun accepting patients into a new Phase II clinical study to evaluate the efficacy of the innovative Calmare® Pain Therapy medical device utilizing Scrambler Technology versus a sham procedure in treating painful chemotherapy-induced peripheral neuropathy (CIPN). The principal investigator for this study is Toby C. Campbell, M.D., who is a research physician specializing in medical oncology and palliative care at the University of Wisconsin Carbone Cancer Center.
